Efficacy of Vitamin D on Vulvovaginal Atrophy in Menopausal Women: A randomized controlled trial
Thai Journal of Obstetrics and Gynaecology · 01.01.2025
DOI: 10.14456/tjog.2025.15 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Thai Journal of Obstetrics and Gynaecology, erschienen am 01.01.2025. Verfasst von Chirocha Hengphrathani.
Abstract (Originalsprache)
Objectives
To evaluate the efficacy of oral vitamin D supplementation in improving vulvovaginal atrophy in postmenopausal women over a 12-week period.Materials and Methods: A double-blind randomized controlled trial involved 48 postmenopausal women with vulvovaginal atrophy. Participants were assigned to receive either 60,000 IU ergocalciferol weekly or placebo. Blinding was applied to both participants and healthcare providers. The primary outcome was vaginal maturation value (VMV) at 12 weeks. Secondary outcomes included VMV at 6 weeks, vaginal atrophy symptoms (VAS), modified vaginal health index (mVHI), vaginal atrophy score (VVA), vitamin D levels, and vaginal pH at 6 and 12 weeks.
Results
Baseline characteristics were not statistically significant between the two groups. In the intention-to-treat analysis, at 12 weeks after treatment, the vitamin D group exhibited significantly higher VMV compared with placebo (47.8 ± 25.24 and 27.4 ± 29.31, p = 0.027) and increased superficial cell count (p = 0.036). Furthermore, significant improvements in vaginal health index were observed in the vitamin D group at 6 and 12 weeks after treatment (VAS: p = 0.030 and p < 0.001, mVHI: p < 0.001 and p < 0.001, VVA: p < 0.001 and p < 0.001, vaginal pH: p = 0.001 and p < 0.001, vitamin D level: p < 0.001 and p < 0.001).
Conclusion
Vitamin D demonstrated superior efficacy over placebo in treating vulvovaginal atrophy in postmenopausal women. Those administered with vitamin D exhibited statistically significant enhancements in vaginal health index, including increased VMV, mVHI, and vitamin D levels, alongside decreased VAS, VVA, and vaginal pH. Therefore, vitamin D may be considered as an alternative treatment option for menopausal women with vulvovaginal atrophy, particularly in those with contraindications to hormone replacement therapy, vitamin D insufficiency, and vitamin D deficiency.
Schlagwörter
Zitieren
APA
Hengphrathani, C. (2025). Efficacy of Vitamin D on Vulvovaginal Atrophy in Menopausal Women: A randomized controlled trial. Thai Journal of Obstetrics and Gynaecology. https://doi.org/10.14456/tjog.2025.15
Vancouver
Hengphrathani C. Efficacy of Vitamin D on Vulvovaginal Atrophy in Menopausal Women: A randomized controlled trial. Thai Journal of Obstetrics and Gynaecology. 2025. doi:10.14456/tjog.2025.15
BibTeX
@article{Hengphrathani2025,
author = {Hengphrathani, Chirocha},
title = {Efficacy of Vitamin D on Vulvovaginal Atrophy in Menopausal Women: A randomized controlled trial},
journal = {Thai Journal of Obstetrics and Gynaecology},
year = {2025},
doi = {10.14456/tjog.2025.15}
}
EUVIMED